Lupin and Yoshindo JV YL Biologics announces success global phase III clinical trial
For Etanercept biosimilar in Rheumatoid Arthritis
YL Biologics announced that a global phase III clinical trial of its investigational Etanercept biosimilar (YLB113) has met with successful outcome. YLB is the joint venture of Lupin and Yoshindo in Japan.The study was conducted at 110 rheumatology clinics across Japan, Europe and India.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content